PARP1 and triple-negative breast carcinoma: In order to understand whether genes involved in NAD+ metabolism, other than PARP1, might be synthetic lethal with BRCA-gene defects, we carried out parallel siRNA screens in isogenic BRCA1-defective and BRCA1-proficient triple-negative breast cancer cell lines.